Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

Study summary

The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery. White light uses many wavelengths of light. NBI only uses two wavelengths which highlight the blood vessels. This makes it easier for the surgeon to see blood vessels. Tumors often have more blood vessels than normal tissue. As a result, NBI may make it easier for the surgeon to see small tumors. In this study the surgeon will look with both normal white light and NBI. This way a comparison can be made to determine which is superior. Improved identification of tumors allows doctors and patients to make informed decisions about whether treatment is needed after surgery. It also provides additional information to determine which treatments may be best.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedNarrow Band Imaging (NBI)

The study team can explain what participation involves.

Who it may be forEndometrial Cancer · Fallopian Tube Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 7, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Other: Narrow Band Imaging (NBI)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Study topics

After surgery (adjuvant)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients must meet one (or more) of the following criteria:
Preoperative diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma (all stage, grade and histology)
Preoperative diagnosis of grade III endometrial carcinoma (all stage, all histology)
Preoperative diagnosis of uterine serous carcinoma (all stage, all grade)
Preoperative diagnosis of clear cell endometrial carcinoma (all stage, all grade)
Preoperative diagnosis of endometrial carcinosarcoma (all stage, all grade)
Gastrointestinal carcinoma (all histology, stage and grade)
Pancreatic carcinoma (all histology, stage and grade)
Lung cancer (all histology, stage and grade)
Esophageal carcinoma (all histology, stage and grade)
Suspected or pathologically confirmed metastatic disease to the lung (all disease primaries)
Suspected or pathologically confirmed malignant pleural effusion (all disease primaries) Patients must meet all of the following criteria:
Planned thorascopic robotic or laparoscopic surgical approach
\>18 years old
Not pregnant
Able to give consent Participation in other research protocols does not exclude a patient from participation in this study.

Reasons someone may not be able to joinExclusion criteria

None

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 7, 2018. Always confirm current availability with the study team.

View original record ↗